Intercept Pharma (ICPT) Announces Phase 3 REVERSE Trial Evaluating OCA for Treatment of NASH Patients with Compensated Cirrhosis
Tweet Send to a Friend
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
